RecruitingNCT07412990

GRASS (Grass MATA MPL Real-world Assessment Study)

Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern


Sponsor

Allergy Therapeutics

Enrollment

1,000 participants

Start Date

Mar 11, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who
  • are male and female patients
  • are 18 years of age or older
  • treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
  • Patients will only be enrolled in the study after the treatment decision has been made

Exclusion Criteria3

  • At the physician's discretion, the study should not be offered to the following patients:
  • Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.
  • In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGrassmuno®

SCIT for grass pollen allergy, observational study


Locations(1)

Dr. Kasche

Hamburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07412990


Related Trials